위고비® 오남용: 비만 약물 치료 방향과 정책에 대한 제언

초록

Wegovy®, an anti-obesity medication approved in South Korea in April 2023, has attracted attention for its significant weight loss and cardiovascular benefits. However, concerns regarding its misuse have arisen since its release. The drug is being prescribed through telemedicine and sold illegally online, often to individuals without obesity who seek it for cosmetic purposes, and sometimes without proper medical supervision. This misuse increases the risk of serious side effects, including gastrointestinal issues and potential complications such as cholecystitis and pancreatitis. Furthermore, the misuse of Wegovy® exacerbates health inequalities. Due to distorted pricing, patients who truly need the treatment may have to pay additional costs beyond the appropriate price, or face difficulty accessing the drug together. This situation can create disparities in access to medication based on socioeconomic status. Health authorities should recognize obesity as a chronic condition that significantly impacts public health. They should seriously consider policy changes to provide health insurance coverage for obesity treatment and medication, especially for individuals with severe cases. Stricter regulations on online sales, telemedicine prescriptions, and increased public awareness are also essential to prevent misuse and improve access for those in genuine need. Additionally, continuous monitoring of drug usage and adverse events is crucial to ensure its proper use. Ultimately, a collaborative effort from the medical community, the public, and health authorities is necessary to ensure the appropriate use of Wegovy®, minimize health risks, and improve equitable access to treatment for obesity.

키워드